long intergenic non-protein coding RNA 1966Genealiases: []
Q-omics provides the consensus-scored LINC01966 profile across patient tissues and cancer cell-line models. LINC01966 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LINC01966 is differentially expressed in 1, with the highest sampling consensus in LIHC. Additionally, LINC01966 RNA expression shows 6,244 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight BLCA, LIHC, and COAD as cancer lineages where LINC01966 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01966 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01966 survival associations across molecular data types. LINC01966 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01966 RNA expression–survival associations across cancer types. High LINC01966 expression shows unfavorable associations in BLCA, CESC, TGCT, UCS, THCA and LIHC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .009). Together, the overview and detailed table identify BLCA as the clearest survival context for LINC01966 RNA expression.
This table summarizes LINC01966 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01966. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01966 shows higher tumor expression in LIHC. The LIHC box plot shows higher LINC01966 RNA expression in tumor versus normal tissue (log2 FC = +0.012, t-test p = .014).
This table shows molecular features associated with LINC01966 in patient tissues and cancer cell lines. In patient samples, LINC01966 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
